[go: up one dir, main page]

CA2544381A1 - Methods for administration of a farnesyl dibenzodiazepinone - Google Patents

Methods for administration of a farnesyl dibenzodiazepinone Download PDF

Info

Publication number
CA2544381A1
CA2544381A1 CA002544381A CA2544381A CA2544381A1 CA 2544381 A1 CA2544381 A1 CA 2544381A1 CA 002544381 A CA002544381 A CA 002544381A CA 2544381 A CA2544381 A CA 2544381A CA 2544381 A1 CA2544381 A1 CA 2544381A1
Authority
CA
Canada
Prior art keywords
methods
administration
formula
farnesyl dibenzodiazepinone
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002544381A
Other languages
French (fr)
Other versions
CA2544381C (en
Inventor
Henriette Gourdeau
Maxime Ranger
Francois Berger
Bryan Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thallion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002507567A external-priority patent/CA2507567A1/en
Application filed by Individual filed Critical Individual
Priority to CA002544381A priority Critical patent/CA2544381C/en
Publication of CA2544381A1 publication Critical patent/CA2544381A1/en
Application granted granted Critical
Publication of CA2544381C publication Critical patent/CA2544381C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms by administration of the farnesylated dibenzodiazepinone compound of Formula I via continuous intravenous infusion. The invention includes pharmaceutical compositions comprising the compound of Formula I: (see formula I)
CA002544381A 2005-05-16 2006-05-16 Methods for administration of a farnesyl dibenzodiazepinone Expired - Fee Related CA2544381C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002544381A CA2544381C (en) 2005-05-16 2006-05-16 Methods for administration of a farnesyl dibenzodiazepinone

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CACA2,507,567 2005-05-16
CA002507567A CA2507567A1 (en) 2004-09-27 2005-05-16 Use of compositions comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions
CA002544381A CA2544381C (en) 2005-05-16 2006-05-16 Methods for administration of a farnesyl dibenzodiazepinone

Publications (2)

Publication Number Publication Date
CA2544381A1 true CA2544381A1 (en) 2006-07-29
CA2544381C CA2544381C (en) 2007-07-31

Family

ID=36702810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002544381A Expired - Fee Related CA2544381C (en) 2005-05-16 2006-05-16 Methods for administration of a farnesyl dibenzodiazepinone

Country Status (1)

Country Link
CA (1) CA2544381C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131365A1 (en) * 2006-05-16 2007-11-22 Thallion Pharmaceuticals Inc. Treatment of neoplastic disorders using a farnesyl dibenzodiazepinone administered by continuous intravenous infusion

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763604B2 (en) 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
WO2007131365A1 (en) * 2006-05-16 2007-11-22 Thallion Pharmaceuticals Inc. Treatment of neoplastic disorders using a farnesyl dibenzodiazepinone administered by continuous intravenous infusion

Also Published As

Publication number Publication date
CA2544381C (en) 2007-07-31

Similar Documents

Publication Publication Date Title
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
MX2009006742A (en) Novel compounds.
MX2011012122A (en) Thiophene derivatives.
UA97351C2 (en) Coumarin derivative having antitumor activity
WO2009016410A3 (en) Chemical compounds 831
WO2009073148A3 (en) Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
HK1139658A1 (en) Benzimidazole derivatives
MX2009004096A (en) Talarazole metabolites.
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
EP2215054B8 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2005115470A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
WO2009015368A3 (en) Multikinase inhibitors for use in the treatment of cancer
TW200626158A (en) Naphthaline derivatives
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2006099410A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007095021A3 (en) Novel compounds
WO2008093838A1 (en) Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140516